Patents by Inventor Jean-Philippe Bürckert

Jean-Philippe Bürckert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM 2DD8
    Publication number: 20230272051
    Abstract: This disclosure provides antibodies and antigen-binding fragments that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments herein can be used to diagnose a SARS-CoV-2 infection.
    Type: Application
    Filed: September 23, 2022
    Publication date: August 31, 2023
    Inventors: Jacob Glanville, Shahrad Daraeikia, I-Chieh Wang, Sindy Andrea Liao Chan, Jean-Philippe Bürckert, Sawsan Youssef
  • OPTIMIZED VACCINE COMPOSITIONS AND METHODS FOR MAKING THE SAME
    Publication number: 20220088175
    Abstract: Described herein are compositions of and methods of making vaccines which can provide broad serological reactivity an inverse dose response, and a swarm effect.
    Type: Application
    Filed: August 10, 2021
    Publication date: March 24, 2022
    Inventors: Jacob GLANVILLE, Sarah IVES, Michal IZHAKY, Sawsan YOUSSEF, Jean-Philippe BÜRCKERT
  • Anti-SARS-Cov-2 antibodies derived from 6nb6
    Patent number: 11053304
    Abstract: This disclosure provides antibodies and antigen-binding fragments that are derived from 6nb6 and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments herein can be used to diagnose a SARS CoV 2 infection.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: July 6, 2021
    Assignee: Centivax, Inc.
    Inventors: Jacob Glanville, Shahrad Daraeikia, I-Chieh Wang, Sindy Andrea Liao-Chan, Jean-Philippe Bürckert, Sawsan Youssef
  • Anti-SARS-Cov-2 antibodies derived from CR3022
    Patent number: 11034762
    Abstract: This disclosure provides antibodies that are derived from CFR3022 and that can be administered to an individual that is infected with a virus. Antibodies herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies herein can be used to diagnose a SARS CoV 2 infection.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 15, 2021
    Assignee: Centivax, Inc.
    Inventors: Jacob Glanville, Shahrad Daraeikia, I-Chieh Wang, Sindy Andrea Liao Chan, Jean-Philippe Bürckert, Sawsan Youssef
  • Anti-SARS-Cov-2 antibodies derived from 3bgf
    Patent number: 11028167
    Abstract: This disclosure provides antibodies and antigen-binding fragments that are derived from 3bgf and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments herein can be used to diagnose a SARS CoV-2 infection.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 8, 2021
    Assignee: Centivax, Inc.
    Inventors: Jacob Glanville, Shahrad Daraeikia, I-Chieh Wang, Sindy Andrea Liao Chan, Jean-Philippe Bürckert, Sawsan Youssef
  • Anti-SARS-CoV-2 antibodies derived from 2DD8
    Patent number: 11028150
    Abstract: This disclosure provides antibodies and antigen-binding fragments that are derived from 2dd8 and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments herein can be used to diagnose a SARS CoV-2 infection.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 8, 2021
    Assignee: Centivax, Inc.
    Inventors: Jacob Glanville, Shahrad Daraeikia, I-Chieh Wang, Sindy Andrea Liao Chan, Jean-Philippe Bürckert, Sawsan Youssef
  • Anti-SARS-Cov-2 antibodies derived from 2GHW
    Patent number: 11021531
    Abstract: This disclosure provides antibodies and antigen-binding fragments that are derived from 2ghw and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments provided herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments provided herein can be used to diagnose a SARS-Cov-2 infection.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 1, 2021
    Assignee: Centivax, Inc.
    Inventors: Jacob Glanville, Shahrad Daraeikia, I-Chieh Wang, Sindy Andrea Liao-Chan, Jean-Philippe Bürckert, Sawsan Youssef